As CDMOs attend the J.P. Morgan Healthcare Conference in San Francisco, Jan. 13-16, analysts remain cautiously optimistic about the industry’s outlook in 2025.
From biologics to treatments for rare diseases, these drugs will bring unique production challenges that require advanced technologies and precise processes.
Contrasting the fortunes of other hot drug classes, it is possible that cell and gene therapies may have reached their apex. So, where do they go next?
Chris Chen on Wednesday told the J.P. Morgan Healthcare Conference in San Francisco that the Chinese-based CRDMO has become resilient amid the “clouds” of geopolitics.
While an effective disinfectant, the corrosive properties of chloramines can affect the performance and longevity of water treatment equipment. UV offers both economic and physical...
Improve bioreactor performance, accelerate process development from benchtop to production, assess respiratory efficiency with continuous CO2 monitoring, eliminate potential interferenc...
To achieve greater process stability and consistency between batches, it is important to understand both conventional stainless steel bioreactors and the rapidly growing single...
Over time and through repeated use, pH sensors in pharma and biotech applications are affected by their measuring environments. To ensure performance and accurate measurement,...
